Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.9900
0.00 (0.00%)
Jun 5, 2025, 10:25 AM - Market open
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$758,389
Profits / Employee
-$3,256,667
Market Cap
59.06M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18 | 4 | 28.57% |
Dec 31, 2023 | 14 | 5 | 55.56% |
Dec 31, 2022 | 9 | 1 | 12.50% |
Dec 31, 2021 | 8 | 3 | 60.00% |
Dec 31, 2020 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
IRD News
- 3 days ago - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 21 days ago - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 24 days ago - Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewsWire
- 4 weeks ago - Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - GlobeNewsWire
- 7 weeks ago - Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - GlobeNewsWire
- 2 months ago - Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases - GlobeNewsWire
- 2 months ago - Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewsWire